14 Participants Needed

Anti-tumor B for Cancer

MC
Overseen ByMedical College of Wisconsin Cancer Center Clinical Trials Office
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Medical College of Wisconsin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop your current medications. However, you cannot use any medicinal botanical, natural, or other herbal compounds while participating in the trial.

What data supports the idea that Anti-tumor B for Cancer is an effective treatment?

The available research does not provide specific data supporting the effectiveness of Anti-tumor B for Cancer. Instead, it discusses other treatments and strategies, such as the use of Human Beta Defensin (hBD-1) in breast cancer and the effects of emodin and BTB14431 in colonic cancer. Without specific data on Anti-tumor B, we cannot conclude its effectiveness compared to other treatments.12345

What safety data exists for Anti-tumor B (Zeng Sheng Ping) in cancer treatment?

The safety data for Anti-tumor B, also known as Zeng Sheng Ping, is limited in the provided research. The studies primarily focus on its efficacy in cancer prevention and treatment, particularly in inhibiting tumor growth and signaling pathways. However, specific safety data or adverse effects are not detailed in the abstracts provided. Further investigation into clinical trials or detailed studies would be necessary to obtain comprehensive safety data.678910

Is Anti-tumor B a promising drug for cancer?

The information provided does not mention Anti-tumor B or its effects, so we cannot determine if it is a promising drug for cancer based on the given research articles.1112131415

Research Team

Stuart J. Wong, MD | Froedtert & the ...

Stuart J. Wong, MD

Principal Investigator

Medical College of Wisconsin

Eligibility Criteria

Adults over 18 with a new or recurring oral cavity squamous cell cancer, who haven't had systemic chemotherapy for it. They must be fit for surgery and have good organ function. Women of childbearing age must use contraception, and men agree to barrier methods or abstinence.

Inclusion Criteria

- Potassium: > 3 mmol/L or < 6 mmol/L;
My kidney function, based on a formula, is within the required range.
I have a new or returning oral cancer after at least 6 months of remission.
See 35 more

Exclusion Criteria

I do not have severe health issues like uncontrolled heart disease or severe lung problems.
I am currently using herbal or natural remedies.
I have had chemotherapy for oral cancer but not for other cancers.
See 3 more

Treatment Details

Interventions

  • Anti-tumor B
  • Placebos
Trial OverviewThe trial is testing Anti-tumor B, made from six Chinese herbs, against a placebo in patients with oral cancer. It's randomized and double-blinded, meaning neither the doctors nor the patients know who gets the real treatment versus the placebo.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Anti-tumor BExperimental Treatment1 Intervention
1,200 mg three times a day.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials
645
Recruited
1,180,000+

Findings from Research

Human Beta Defensin (hBD-1) is a potential biomarker for breast cancer, particularly triple negative breast cancer (TNBC), as its loss is associated with tumor progression and resistance to chemotherapy.
The novel approach of A priori Activation of Apoptosis Pathways of Tumor (AAAPT) using hBD-1 in a TNBC mouse model demonstrated significant tumor volume reduction by sensitizing resistant cancer cells to the chemotherapy drug Doxorubicin, suggesting a way to enhance treatment efficacy while potentially reducing side effects.
Restoration of the Lost Human Beta Defensin (hBD-1) in Cancer as a Strategy to Improve the Efficacy of Chemotherapy.Pandurangi, RS., Sekar, TV., Paulmurugan, R.[2023]
In a study involving 100 rats with colon cancer, both low-dose BTB14431 and emodin significantly reduced total tumor weight when administered intravenously, indicating their potential as effective cancer treatments.
High-dose emodin also showed anti-cancer effects, particularly in reducing intraperitoneal tumor weight, while the optimal dosing for both compounds remains to be determined for maximum efficacy.
Anti-tumorigenic Effects of Emodin and Its' Homologue BTB14431 on Vascularized Colonic Cancer in a Rat Model.Höhn, P., Braumann, C., Freiburger, M., et al.[2020]
In a rat model, both BTB14431 and emodin showed no significant tumor-suppressing effects when administered intraperitoneally or intravenously, despite previous in vitro evidence of their anti-tumor properties.
Higher doses of emodin were associated with an increased mortality rate, indicating potential safety concerns that need to be addressed in future studies.
Dose-dependent role of novel agents emodin and BTB14431 in colonic cancer treatment in rats.Braumann, C., Koplin, G., Geier, C., et al.[2018]

References

Restoration of the Lost Human Beta Defensin (hBD-1) in Cancer as a Strategy to Improve the Efficacy of Chemotherapy. [2023]
Anti-tumorigenic Effects of Emodin and Its' Homologue BTB14431 on Vascularized Colonic Cancer in a Rat Model. [2020]
Dose-dependent role of novel agents emodin and BTB14431 in colonic cancer treatment in rats. [2018]
Overexpression of Metastatic Related MicroRNAs, Mir-335 and Mir-10b, by Staphylococcal Enterotoxin B in the Metastatic Breast Cancer Cell Line. [2020]
Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. [2018]
Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling. [2021]
Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping(Antitumor B). [2022]
Efficacy and safety of Shen-Ling-Bai-Zhu-San combined with chemotherapy for lung cancer: A protocol for systematic review and meta-analysis. [2023]
Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Aqueous extract of Bambusae Caulis in Taeniam inhibits PMA-induced tumor cell invasion and pulmonary metastasis: suppression of NF-κB activation through ROS signaling. [2021]
[Effect of ACBP-S on cell cycle and apoptosis in human gastric cancer cells]. [2011]
Antitumor effects of snake venom chemically modified Lys49 phospholipase A2-like BthTX-I and a synthetic peptide derived from its C-terminal region. [2022]
ACBP suppresses the proliferation, migration, and invasion of colorectal cancer via targeting Wnt/beta-catenin signaling pathway. [2021]
14.United Statespubmed.ncbi.nlm.nih.gov
Ginsenoside (20S)-protopanaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells. [2021]
Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A). [2021]